iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) and Fate Therapeutics (NASDAQ:FATE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
Risk and Volatility
iTeos Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.
Earnings and Valuation
This table compares iTeos Therapeutics and Fate Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iTeos Therapeutics | $12.60 million | 21.48 | -$112.64 million | ($3.15) | -2.35 |
| Fate Therapeutics | $13.45 million | 12.03 | -$160.93 million | ($1.65) | -0.86 |
Insider and Institutional Ownership
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares iTeos Therapeutics and Fate Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iTeos Therapeutics | N/A | -20.11% | -17.50% |
| Fate Therapeutics | -1,325.43% | -45.88% | -33.95% |
Analyst Ratings
This is a summary of current ratings and target prices for iTeos Therapeutics and Fate Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iTeos Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| Fate Therapeutics | 0 | 7 | 3 | 0 | 2.30 |
iTeos Therapeutics currently has a consensus price target of $22.25, suggesting a potential upside of 200.27%. Fate Therapeutics has a consensus price target of $6.75, suggesting a potential upside of 375.35%. Given Fate Therapeutics’ higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than iTeos Therapeutics.
Summary
iTeos Therapeutics beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks.
About iTeos Therapeutics
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
